Ann: Investor Presentation - Non-deal Roadshow, page-21

Tilrays takeover of Illera Healthcare is dependent on revenue targets being met for the takeover terms to proceed - the only products available to sustain that revenue generation is what you see in this presentation, apart from the original licence agreement (terms of which are non disclosed)
The co-habitation recently of zelira and Illera releasing double branded product promotional flyers to market would suggest they are pivoting yet again to meet the terms of the tilray agreement and demonstrate revenue streams are imminent.....this at the possible expense of the trial results being finalised and released to substantiate that the product is progressing down the path to efficacy....seems a little ill thought and rushed in my view.....and contrary to what the roadshows of recent months have suggested was the strategic goal......the rejigged presentation has all potential licence partners removed from it no ( hence rejigged) so they are now not disclosing the whys, the wheres, the hows.....etc etc.......pretty non plussed really...market seems to agree